Bright Minds Biosciences (DRUG) said Tuesday that its BMB-101 showed a complete elimination of drop attacks in the DBA/2 mouse model of epilepsy.
"Notably, BMB-101 achieved 100% survival in the DBA/2 model, reversing brainstem serotonin deficits and preventing seizure-induced respiratory arrest," Jan Torleif Pedersen, the company's chief science officer, said.
The company said the findings demonstrate the potential of BMB-101 to address critical gaps in the prevention of sudden unexpected death in epilepsy.
Shares of Bright Minds Biosciences rose more than 11% in recent trading.
Price: 36.43, Change: +3.81, Percent Change: +11.68
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。